We are live on ! Find out more
SFCM

Seven Fleet Capital Management Portfolio holdings

AUM $318M
This Fund
S&P 500
This Quarter Est. Return
+43.96%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$148M
AUM Growth
–
Cap. Flow
+$138M
Cap. Flow %
93.63%
Top 10 Hldgs %
68.44%
Holding
85
New
85
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$62.7M
2
SLNO
Soleno Therapeutics
SLNO
+$7.13M
3
COGT icon
Cogent Biosciences
COGT
+$6.02M
4
RVMD icon
Revolution Medicines
RVMD
+$4.31M
5
TERN
Terns Pharmaceuticals
TERN
+$3.01M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
26
Madrigal Pharmaceuticals
MDGL
$11.8B
$1.08M 0.73%
+1,860
New +$950K
GERN icon
27
Geron
GERN
$949M
$1.03M 0.69%
+777,880
New +$976K
KRYS icon
28
Krystal Biotech
KRYS
$9.66B
$986K 0.67%
+4,000
New +$842K
LONA
29
LeonaBio Inc
LONA
$72.1M
$969K 0.66%
+127,951
New +$586K
TSHA icon
30
Taysha Gene Therapies
TSHA
$1.89B
$920K 0.62%
+167,223
New +$812K
SLN
31
Silence Therapeutics
SLN
$564M
$897K 0.61%
+147,600
New +$945K
ZURA icon
32
Zura Bio
ZURA
$567M
$872K 0.59%
+166,500
New +$658K
AGIO icon
33
Agios Pharmaceuticals
AGIO
$1.93B
$864K 0.58%
+31,738
New +$1.11M
CELC icon
34
Celcuity
CELC
$4.52B
$832K 0.56%
+8,338
New +$685K
PRAX icon
35
Praxis Precision Medicines
PRAX
$10.1B
$796K 0.54%
+2,700
New +$503K
KALV
36
DELISTED
KalVista Pharmaceuticals
KALV
$782K 0.53%
+48,412
New +$641K
PALI icon
37
Palisade Bio
PALI
$367M
$770K 0.52%
+327,500
New +$630K
RLMD icon
38
Relmada Therapeutics
RLMD
$527M
$744K 0.5%
+154,109
New +$516K
PTGX icon
39
Protagonist Therapeutics
PTGX
$9.44B
$699K 0.47%
+8,000
New +$655K
CDTX
40
DELISTED
Cidara Therapeutics
CDTX
$668K 0.45%
+3,026
New +$489K
CYTK icon
41
Cytokinetics
CYTK
$10.4B
$657K 0.44%
+10,335
New +$643K
NKTR icon
42
Nektar Therapeutics
NKTR
$2.58B
$634K 0.43%
+15,000
New +$839K
UTHR icon
43
United Therapeutics
UTHR
$23.1B
$633K 0.43%
+1,300
New +$605K
RLAY icon
44
Relay Therapeutics
RLAY
$4.33B
$618K 0.42%
+73,000
New +$521K
DNTH icon
45
Dianthus Therapeutics
DNTH
$6.09B
$604K 0.41%
+14,651
New +$568K
MBX
46
MBX Biosciences
MBX
$3.27B
$574K 0.39%
+18,200
New +$442K
EOLS icon
47
Evolus
EOLS
$501M
$545K 0.37%
+82,000
New +$556K
ZYME icon
48
Zymeworks
ZYME
$1.67B
$542K 0.37%
+20,600
New +$449K
CRBP icon
49
Corbus Pharmaceuticals
CRBP
$190M
$462K 0.31%
+56,750
New +$700K
VRDN icon
50
Viridian Therapeutics
VRDN
$2.67B
$456K 0.31%
+14,654
New +$402K
1
2
3 4

Similar funds

CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
SA
SAM Advisors Oakhurst, California $319M AUM 17.08% 1-Year Est. Return
TM
TigerOak Management Albuquerque, New Mexico $317M AUM 25.39% 1-Year Est. Return
GWP
Gen-Wealth Partners Zeeland, Michigan $317M AUM 17.24% 1-Year Est. Return
FPWM
FSB Premier Wealth Management Waterloo, Iowa $319M AUM 15.64% 1-Year Est. Return
KI
Keewaydin Investments Southampton, New York $317M AUM
CPH
C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return
SGF
Stephens Greth Foundation Dallas, Texas $320M AUM

Seven Fleet Capital Management's Q4 2025 Portfolio in Review

Q4 2025 is the first quarter with a 13F filing on record for Seven Fleet Capital Management, which disclosed 85 positions worth $148M. Its ten largest holdings account for 68% of the portfolio.

Its largest position is CG Oncology: 1,515,151 shares worth $62.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Seven Fleet Capital Management's largest Q4 2025 buy was CG Oncology: 1,515,151 shares worth $62.9M.
  • Seven Fleet Capital Management's ten largest holdings make up 68% of its $148M portfolio in Q4 2025.
  • Seven Fleet Capital Management disclosed 85 positions in Q4 2025, its first 13F filing on record.

Based on Seven Fleet Capital Management's 13F filing for Q4 2025, filed 26 Feb 2026.